Charlie Adams

Prix à l'honneur

Legal 500 UK 2026

Leading associate in the life sciences and healthcare category.

Charlie is a senior counsel in our Cambridge office specialising in the commercialisation of intellectual property in the life sciences and technology sectors.

Charlie specialises in the commercialisation of intellectual property in the life sciences and technology sectors. He works with clients on key strategic transactions throughout their lifecycle. This ranges from advising start-ups on foundational licensing deals and R&D collaborations through to working with established multinational companies on distribution, manufacturing and other commercial arrangements. He also advises on the IP, commercial and regulatory aspects of VC investment and M&A.

With over a decade of experience in the Cambridge ecosystem, Charlie has a particular focus on leveraging his later-stage experience when advising early-stage clients and regularly delivers training to new founders taking part in life sciences incubators and accelerators throughout the UK.

CV

Since 2025 Senior Counsel, Taylor Wessing

2022 - 2025 Senior Associate, Taylor Wessing

2020 - 2022 Associate, Taylor Wessing

Carrière

Since 2025 Senior Counsel, Taylor Wessing

2022 - 2025 Senior Associate, Taylor Wessing

2020 - 2022 Associate, Taylor Wessing

Formation

2014 LPC, BPP Law School

2013 Graduate diploma in law, BPP Law School

2011 BA Philosophy and social anthropology, University of Cambridge

Prix et distinctions

Legal 500 UK 2026

Featured

Legal 500 UK 2025

Legal 500 UK 2022

Experience

Advising SENISCA on its partnership with L'Oréal

We have advised SENISCA, a University of Exeter spin-out, on a multi-year joint research, development and commercialisation licence agreement with L'Oréal.

Press release

Charlie Adams

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release

Ross McNaughton

Elinor Picton

Oli Denne

Helen Farr

Adrian Toutoungi

Charlie Adams

Nicholas Vollers

Ed Chapman

Advising Antiverse on its collaboration with Nxera Pharma

We have advised Antiverse on its multi-target partnership and licensing agreement with Nxera Pharma (Nxera) to design antibodies for G-protein coupled receptors (GPCRs) using generative artificial intelligence.

Press release

Charlie Adams

Advising Cumulus Oncology on its exclusive GPR68 licence and development collaboration

Advising Cumulus Oncology on its collaboration agreement with leadXpro to develop small molecules against GPR68, an important proton sensing G protein coupled receptor.

Press release

Nicholas Vollers

Charlie Adams

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Andrew Edge

Howard Palmer

Oli Denne

Charlie Adams

Advising Theramex

Advised Theramex, a leading global speciality pharmaceutical company dedicated to women's health, on its exclusive licensing agreement with Radius Health Inc for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.

Press release

Charlie Adams